5^th Annual Congress on Clinical & Hospital Pharmacy April 22-23, 2019 Tokyo, Japan

Ayman M Noreddin received his PhD in Pharmaceutical Sciences from the University of the Pacific, California and received research training as a visiting scholar at the Department of Medicine, Stanford University. He had Post-doctoral fellowship (Pharmacokinetics and Pharmacodynamics of Antimicrobials), Department of Medical Microbiology, University of Manitoba followed by an American College of Clinical Pharmacy postdoctoral fellowship (Infectious Diseases). His research interest includes Pharmacoklinetic/Pharmacodynamic modeling of anti-infective and anti-cancer therapy, clinical simulation and Monte Carlo analysis and bacterial resistance in biofilm studies. He has outstanding records of scientific and academic accomplishments with multiple research funding, numerous publications in highly prestigious journals and various presentations in both national and international conferences. He served as a scientific reviewer for the NIH as well as other national and international research institutions.

• Pharmacoklinetic/Pharmacodynamic modeling of anti-infective and anti-cancer therapy • Clinical simulation and Monte Carlo analysis • Bacterial resistance in biofilm studies • Minority health care studies Research Focus • Anti-infective translational research in relation to antimicrobial resistance: Our goal is to improve patient care by maximizing clinical outcomes and preventing the development of bacterial resistance . • Anti-Cancer translational research in relation to 3D modeling and epigenetic studies: Our goal is to optimize cancer chemotherapy and overcome/reverse the development of resistance.

Kazuo Nakamura has completed his Ph.D. at the age of 37 years from Kagoshima University and postdoctoral studies from Department of Clinical Pharmacy and Pharmacology, Graduate School of Medical and Dental Sciences, Kagoshima University. He is the professor of Nihon Pharmaceutical University. He has published more than 25 papers in reputed journals and serving as a councilor of The Japanese Pharmacological Society.

Prescription contruction and analysis, Nutrition and Immunity, Clinical Pharmacology, Pharmaceutical Science.

Bernard Cheung graduated from the University of Cambridge. He was a British Heart Foundation Junior Research Fellow at Cambridge before taking up lectureships in Sheffield and Hong Kong. In 2007-2009, he held the chair in Clinical Pharmacology and Therapeutics in Birmingham. He heads the Division of Clinical Pharmacology and Therapeutics in the Department of Medicine of the University of Hong Kong. He is an Honorary Consultant Physician of Queen Mary Hospital and the Medical Director of the Phase 1 Clinical Trials Centre. He is the Editor-in-Chief of Postgraduate Medical Journal.

Prof Cheung’s main research interest is in cardiovascular diseases and risk factors, including hypertension and the metabolic syndrome. He has 270 publications, 7500 citations and an h-index of 43.

He is Dr. Mojtaba Mafi M.D., Medical Doctor/ Physician, graduated from Tehran university, School of Medicine with honor.He studied in neurosurgery ward and graduated with A score with thesis on Meningioma Brain Tumor during 6 years.With continuing my practice with special consideration on psychosomatic disorders,he completed many post graduate courses on health psychology, addiction medicine, sexual disorders therapy successfully.He passed many post graduate courses in Neuro, approved by Medical sciences university. As well, He have been passed post graduate courses on Nutrition,Gastroenterology and hepatology,Obesity treatment and diabetes approved by Tehran University of Medical sciences.He successfully passed more than 10 programs with certificates and membership in Iranian Association of Gastroenterology and Hematology.

He working clinically on patients with Brain Tumor and publishing his results on these topics: 1. Recurrent Meningioma 2. Trigeminal neuralgia 3. Radiation induced meningioma 4. Behavioral change in Brain Tumors 5. DVT prevalence and management among patients with meningioma And some others.